The company needed a hit in its spine trial, and it claims to have got one.
While praising Novartis for kickstarting the CAR-T revolution, the chief exec of Tmunity has no doubt where cell therapy’s development engine really lies.
Its gene therapy is three years away from market, but Mustang is already thinking about outcomes-based pricing.
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.
A Baylor College study suggests to investors what Bellicum’s upcoming first-in-human trial of BPX-603 will have to match.
The UK ortho and woundcare group might yet pounce on Nuvasive.
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
After a trial failure last week, Caladrius Biosciences has not abandoned hope for its T regulatory cell therapy in type 1 diabetes, but funding might become a problem.